The Tower, Trinity TEC
About Inflazome Ltd.Utilizing the scientific expertise of our founders and advisors, Inflazome is leading the way in developing orally available drugs to address clinical unmet needs in inflammatory diseases by targeting the inflammasome, which is now thought to drive many chronic inflammatory conditions.
Founder: Matt Cooper and Luke O’Neill
9 articles with Inflazome Ltd.
April 11 is World Parkinson’s Day, designed to raise awareness of Parkinson’s disease. Parkinson’s is a progressive disease of the nervous system that affects movement.
3/26/2019Foundations increasingly play a large role in funding basic science both domestically and internationally. Recently, The Michael J. Fox Foundation for Parkinson’s Research (MJFF) granted Dublin and Cambridge, UK-based Inflazome more than $1 million.
Funding in excess of US$1 million to support the development of a brain imaging probe for patient diagnosis and the clinical development of drugs to treat neurodegenerative diseases
Distinguished scientist with deep expertise in innate immunity and its role in neurodegenerative diseases
12/3/2018Biotechs and pharmas strengthened their leadership teams with these appointments. Find news from Mersana, Foamix, Allergan, and more.
Industry veteran clinician to lead the clinical development of Inflazome’s pioneering NLRP3 inflammasome inhibitors to treat inflammatory diseases
Inflazome Completes €40m ($46m) Series B Financing to Develop NLRP3 Inflammasome Inhibitors to Clinical Proof-of-Concept
Financing led by Forbion, with Longitude Capital and founding investors, Novartis Venture Fund and Fountain Healthcare Partners, also participating
Innovative research was funded by The Michael J. Fox Foundation for Parkinson’s Research and the Shake It Up Australia Foundation
Inflazome today announces the appointment of Prof. Paul Ridker to Inflazome’s Scientific Advisory Board.